Monte Rosa Therapeutics, Inc. (GLUE) 8-K Current Report — March 17, 2026
Filed: March 17, 2026
Health Care
Biological Products, (No Diagnostic Substances)Monte Rosa Therapeutics, Inc. (GLUE) 8-K current report filed with SEC EDGAR on March 17, 2026. This page provides AI-powered analysis of reported events and material disclosures, including results of operations, corporate governance changes, agreements, and other triggering events as disclosed under Form 8-K item codes.
Reported 8-K Items1 item
- Item 2.02: Results of Operations and Financial Condition
Monte Rosa Therapeutics, Inc. 8-K Mar 17, 2026 Event Analysis
Item 2.02 · Results of Operations and Financial Condition
- • Q4 2025 earnings released March 17, 2026 — full results in Exhibit 99.1 of this filing
- • No financial figures disclosed in this item; all key metrics (cash, R&D spend, net loss) in the press release exhibit
Get deeper insights on Monte Rosa Therapeutics, Inc.
Access full AI analysis, insider trading data, fund holdings, and cross-signal detection on SignalX.